Smoking and mental health - NCSCT

Smoking and mental health
60 Fontaine KR, Heo M, Harrigan EP, et al. Estimating the consequences of antipsychotic
induced weight gain on health and mortality rate. Psychiatry Research
2001;101:277–88.
61 Zevin S, Benowitz NL. Drug Interactions with tobacco smoking: An update. Clinical
Pharmacokinetics 1999;36:425–38.
62 Desai HD, Seabolt J, Jann MW. Smoking in patients receiving psychotropic medications: a
pharmacokinetic perspective. CNS Drugs 2001;15:469–94.
63 Carrillo JA, Herraiz AG, Ramos SI, et al. Role of the smoking-induced cytochrome P450
(CYP)1A2 and polymorphic CYP2D6 in steady-state concentration of olanzapine. Journal
of Clinical Psychopharmacology 2003;23(2):119–27.
64 Seppala NH, Leinonen EVJ, Lehtonen ML, Kari T. Clozapine serum concentrations are
lower in smoking than in non-smoking schizophrenic patients. Pharmacology and
Toxicology 1999;85:244–6.
65 Lowe EJ, Ackman ML. Impact of tobacco smoking cessation on stable clozapine or
olanzapine treatment. Annals of Pharmacotherapy 2010;44:727–32.
66 Zullino DF, Delessert D, Eap CB, Preisig M, Baumann P. Tobacco and cannabis smoking
cessation can lead to intoxication with clozapine or olanzapine. International Clinical
Psychopharmacology 2002;17:141–3.
67 Derenne JL, Baldessarini RJ. Clozapine toxicity associated with smoking cessation: case
report. American Journal of Therapeutics 2005;12:469–71.
68 Taylor D, Paton C, Kapur S. The South London and Maudsley & Oxleas NHS Foundation
Trust Prescribing Guidelines, 11th edn. London: Informa Healthcare, 2012.
69 Benowitz NL, Peng M, Jacob P. Effects of cigarette smoking and carbon monoxide on
chlorzoxazone and caffeine metabolism. Clinical Pharmacology and Therapeutics
2003;74:468–74.
70 Benowitz NL, Hall SM, Gunnard M. Persistent increase in caffeine concentrations in
people who stop smoking. British Medical Journal 1989;298:1075–6.
71 Gandhi KK, Williams JM, Menza M, Galazyn M, Benowitz NL. Higher serum caffeine in
smokers with schizophrenia compared to smoking controls. Drug and Alcohol Dependence
2010;110:151–5.
72 World Health Organization. International Statistical Classification of Diseases and Related
Health Problems – 10th revision. Geneva: WHO, 1990.
73 Breslau N, Kilbey MM, Andreski P. Nicotine withdrawal symptoms and psychiatric
disorders: findings from an epidemiologic study of young adults. American Journal of
Psychiatry 1992;149:464–9.
74 Gray KM, Baker NL, Carpenter MJ, Lewis AL, Upadhyaya HP. Attention-
Deficit/Hyperactivity Disorder confounds nicotine withdrawal self-report in adolescent
smokers. American Journal on Addictions 2010;19:325–31.
75 Piper ME, Cook JW, Schlam TR, Jorenby DE, Baker TB. Anxiety diagnoses in smokers
seeking cessation treatment: relations with tobacco dependence, withdrawal, outcome and
response to treatment. Addiction 2011;106(:418–27.
76 Tidey JW, Rohsenow DJ, Kaplan GB, Swift RM, Adolfo AB. Effects of smoking abstinence,
smoking cues and nicotine replacement in smokers with schizophrenia and controls.
Nicotine and Tobacco Research 2008;10:1047–56.
77 Allen MH, Debanne M, Lazignac C, et al. Effect of nicotine replacement therapy on
agitation in smokers with schizophrenia: A double-blind, randomized, placebo-controlled
study. American Journal of Psychiatry 2011;168:395–9.
78 George TP, Sernyak MJ, Ziedonis DM, Woods SW. Effects of clozapine on smoking in
chronic schizophrenic outpatients. Journal of Clinical Psychiatry 1995;56:344–6.
108 © Royal College of Physicians 2013